Beimei has established a nearly 3,000-square-meter innovation R&D center for pediatric medicines in the International Biomedical Industrial Park of the Futian Free Trade Zone and Shenzhen Bio-Incubator, and established Beimei Research & Development (Shenzhen) Co. Ltd. in August 2022. Our R&D team has nearly 100 R&D personnel, including PhDs, masters, oversea returnees, and core technical talents, accounting for more than half of Beimei's total employees and providing a strong workforce for the Beimei's high-quality development.

And Beimei has established in-depth and extensive cooperation and exchanges on scientific research projects with China Pharmaceutical University and several domestic and oversea professional drug R&D institutions.

Aiming at the pain points of clinical pediatric medication, Beimei has built three major technology platforms with independent intellectual property rights: pediatric sustained-release formulation, oral thin film and topical transdermal gel, and developed a series of high-end products suitable for children, including inhalation, oral suspension, oral solution, oral thin film and other dosage forms. Furthermore, from the perspective of improving the treatment compliance of pediatric medicines, Beimei has developed innovative taste-masking technology, mixed granulation and other formulation process technologies with independent intellectual property rights, which forms a strong R&D capability of state-of-the-art formulation technology for pediatric prescription medicines.